Ocular Therapeutix, Inc
OCULFigures shown here come from public SEC filings. Dates beside each section show the available history.
How Ocular Therapeutix, Inc Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 14 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 18, 2026. The latest institutional report shown is dated Mar 31, 2026; other ownership filings may exist.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Reported 13F positions
Each row shows what a filer reported for one date, not a current position. The link opens that filing.
| Filer | Report date | Shares | Value | Filing |
|---|---|---|---|---|
| Hilton Head Capital Partners, LLC | 2026-03-31 | 4,520 | $38.3K | SEC filing |
| Kemnay Advisory Services Inc. | 2026-03-31 | 1,675 | $14.2K | SEC filing |
| Farther Finance Advisors, LLC | 2026-03-31 | 1,252 | $10.4K | SEC filing |
| Woodline Partners LP | 2026-03-31 | 1,667,609 | $14.1M | SEC filing |
| LPL Financial LLC | 2026-03-31 | 62,799 | $532K | SEC filing |
| JANUS HENDERSON GROUP PLC | 2026-03-31 | 68,500 | $581K | SEC filing |
| Aberdeen Group plc | 2026-03-31 | 558,380 | $4.73M | SEC filing |
| DEUTSCHE BANK AG\ | 2026-03-31 | 631,741 | $5.35M | SEC filing |
| Raiffeisen Bank International AG | 2026-03-31 | 95,000 | $703K | SEC filing |
| CITADEL ADVISORS LLC | 2026-03-31 | 635,922 | $5.39M | SEC filing |
| TD PRIVATE CLIENT WEALTH LLC | 2026-03-31 | 81 | $686 | SEC filing |
| Assenagon Asset Management S.A. | 2026-03-31 | 45,600 | $386K | SEC filing |
| D. E. Shaw & Co., Inc. | 2026-03-31 | 218,478 | $1.85M | SEC filing |
| Relyea Zuckerberg Hanson LLC | 2026-03-31 | 17,600 | $149K | SEC filing |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | 2026-03-31 | 18,173 | $154K | SEC filing |
| Tower Research Capital LLC (TRC) | 2026-03-31 | 13,449 | $114K | SEC filing |
| BNP PARIBAS FINANCIAL MARKETS | 2026-03-31 | 75,152 | $637K | SEC filing |
| NORTHERN TRUST CORP | 2026-03-31 | 1,525,626 | $12.9M | SEC filing |
| Graham Capital Management, L.P. | 2026-03-31 | 19,118 | $162K | SEC filing |
| Balyasny Asset Management L.P. | 2026-03-31 | 2,692,622 | $22.8M | SEC filing |
120 filers have only one report here.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among Ocular Therapeutix, Inc's recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2026-02-12 · Dugel Pravin: Larger than all 58 other insider sales of Common Stock on file. SEC filing
- 2025-11-05 · Saroj Namrata: Larger than 57 of the 58 other insider sales of Common Stock on file. SEC filing
- 2025-08-25 · Dugel Pravin: Larger than 55 of the 58 other insider sales of Common Stock on file. SEC filing
- 2025-05-23 · Dugel Pravin: Larger than 53 of the 58 other insider sales of Common Stock on file. SEC filing
- 2025-02-24 · Dugel Pravin: Larger than 54 of the 58 other insider sales of Common Stock on file. SEC filing
- 2024-05-23 · Dugel Pravin: Larger than 56 of the 58 other insider sales of Common Stock on file. SEC filing
- 2024-02-26 · SUMMER ROAD LLC: Larger than 16 of the 17 other insider purchases of Common Stock, $0.0001 par value per share on file. SEC filing
- 2023-12-14 · SUMMER ROAD LLC: Larger than all 17 other insider purchases of Common Stock, $0.0001 par value per share on file. SEC filing
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-06-03 | Waheed Nadia · Chief Medical Officer | Common Stock | S — Open market or private sale | −14,828 | 8.27 | SEC filing |
| 2026-05-26 | Kaiser Peter · Chief Development Officer | Common Stock | S — Open market or private sale | −2,967 | 8.20 | SEC filing |
| 2026-05-26 | Dugel Pravin · See Remarks | Common Stock | S — Open market or private sale | −21,156 | 8.20 | SEC filing |
| 2026-05-26 | Heier Jeffrey S. · Chief Scientific Officer | Common Stock | S — Open market or private sale | −3,018 | 8.20 | SEC filing |
| 2026-05-26 | Nayak Sanjay · Chief Strategy Officer | Common Stock | S — Open market or private sale | −1,858 | 8.20 | SEC filing |
| 2026-02-23 | Nayak Sanjay · Chief Strategy Officer | Common Stock | S — Open market or private sale | −1,759 | 8.28 | SEC filing |
| 2026-02-23 | Kaiser Peter · Chief Development Officer | Common Stock | S — Open market or private sale | −2,810 | 8.28 | SEC filing |
| 2026-02-23 | Heier Jeffrey S. · Chief Scientific Officer | Common Stock | S — Open market or private sale | −3,057 | 8.28 | SEC filing |
Showing 8 of 20 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-06-16 | Dugel Pravin · See Remarks | Common Stock | G — Bona fide gift | +50,092 | SEC filing |
| 2026-06-16 | Dugel Pravin · See Remarks | Common Stock | G — Bona fide gift | −50,092 | SEC filing |
| 2026-06-10 | Robins Jason Shand · Chief Financial Officer | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +14,024 | SEC filing |
| 2026-06-10 | Warden Charles M · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +44,000 | SEC filing |
| 2026-06-10 | RAINES MERILEE · Director | Common Stock | A — Grant, award, or other acquisition | +14,000 | SEC filing |
| 2026-06-10 | Williams Leslie J. · Director | Common Stock | A — Grant, award, or other acquisition | +14,000 | SEC filing |
| 2026-06-10 | Graves Adrienne L · Director | Common Stock | A — Grant, award, or other acquisition | +14,000 | SEC filing |
| 2026-06-10 | Warden Charles M · Director | Common Stock | A — Grant, award, or other acquisition | +14,000 | SEC filing |
Showing 8 of 26 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.